[1]

Ikebe T, Okuno R, Uchitani Y, et al. Serotype distribution and antimicrobial resistance of Streptococcus agalactiae isolates in nonpregnant adults with streptococcal toxic shock syndrome in Japan in 2014 to 2021[J]. Microbiol Spectr, 2023, 11(2): e0498722. PMCID: PMC10100893. DOI: 10.1128/spectrum.04987-22 . https://www.ncbi.nlm.nih.gov/pubmed/36786620 Cited in this article [1]

[2]

Kawai S, Miyoshi-Akiyama T, Katano H, et al. Invasive Streptococcus agalactiae (group B Streptococcus) infection with toxic shock-like syndrome: a report of a fatal non-pregnant case and a review of the literature[J]. J Infect Chemother, 2024, 30(1): 71-76. DOI: 10.1016/j.jiac.2023.09.003 . https://www.ncbi.nlm.nih.gov/pubmed/37716644

[3]	Rajack F, Medford S, Ramadan A, et al. Emerging infection: streptococcal toxic shock-like syndrome caused by group B Streptococcus (GBS), Streptococcus agalactiae [J]. Autops Case Rep, 2024, 14: e2024497. PMCID: PMC11253910. DOI: 10.4322/acr.2024.497 . https://www.ncbi.nlm.nih.gov/pubmed/39021470

[4]

Matsuoka N, Kimura T, Endo Y, et al. Streptococcal toxic shock syndrome due to invasive coloproctitis caused by group G Streptococcus: a case report and literature review[J]. Cureus, 2023, 15(11): e48589. PMCID: PMC10710542. DOI: 10.7759/cureus.48589 . https://www.ncbi.nlm.nih.gov/pubmed/38084186 Cited in this article [1]

[5]	Tsao N, Chang YC, Hsieh SY, et al. AR-12 has a bactericidal Activity and a synergistic effect with gentamicin against group A Streptococcus [J]. Int J Mol Sci, 2021, 22(21): 11617. PMCID: PMC8583967. DOI: 10.3390/ijms222111617 . https://www.ncbi.nlm.nih.gov/pubmed/34769046 Cited in this article [4]

[6]	Nelson GE, Pondo T, Toews KA, et al. Epidemiology of invasive group A streptococcal infections in the United States, 2005-2012[J]. Clin Infect Dis, 2016, 63(4): 478-486. PMCID: PMC5776658. DOI: 10.1093/cid/ciw248 . https://www.ncbi.nlm.nih.gov/pubmed/27105747 Cited in this article [1]

[7]	Cascais I, Losa A, Correia C, et al. Toxic shock syndrome: eighteen years of experience in a pediatric intensive care unit[J]. Cureus, 2024, 16(1): e52898. PMCID: PMC10891456. DOI: 10.7759/cureus.52898 . https://www.ncbi.nlm.nih.gov/pubmed/38406070 Cited in this article [2]

[8]	Johnson AF, LaRock CN. Antibiotic treatment, mechanisms for failure, and adjunctive therapies for infections by group A Streptococcus [J]. Front Microbiol, 2021, 12: 760255. PMCID: PMC8601407. DOI: 10.3389/fmicb.2021.760255 . https://www.ncbi.nlm.nih.gov/pubmed/34803985 Cited in this article [1]

[9]	国家儿童感染与过敏性疾病监测中心, 福棠儿童医学发展研究中心, 北京市儿科质控中心, 等. 儿童侵袭性A族链球菌疾病诊断专家共识（2025）[J]. 中华儿科杂志, 2025, 63(3): 238-242. DOI: 10.3760/cma.j.cn112140-20240831-00618 . https://www.ncbi.nlm.nih.gov/pubmed/39979097 Cited in this article [1]

[10]

Mariani F, Gentili C, Pulcinelli V, et al. State of the art of invasive group A Streptococcus infection in children: a scoping review of the literature with a focus on predictors of invasive infection[J]. Children (Basel), 2023, 10(9): 1472. PMCID: PMC10528266. DOI: 10.3390/children10091472 . https://www.ncbi.nlm.nih.gov/pubmed/37761433 Cited in this article [1]

[11]	Factor SH, Levine OS, Schwartz B, et al. Invasive group A streptococcal disease: risk factors for adults[J]. Emerg Infect Dis, 2003, 9(8): 970-977. PMCID: PMC3020599. DOI: 10.3201/eid0908.020745 . https://www.ncbi.nlm.nih.gov/pubmed/12967496 Cited in this article [1]

[12]	Shepherd FR, Davies K, Miners KL, et al. The superantigens SpeC and TSST-1 specifically activate TRBV12-3/12-4+ memory T cells[J]. Commun Biol, 2023, 6(1): 78. PMCID: PMC9854414. DOI: 10.1038/s42003-023-04420-1 . https://www.ncbi.nlm.nih.gov/pubmed/36670205 Cited in this article [1]

[13]	Castro SA, Dorfmueller HC. A brief review on group A Streptococcus pathogenesis and vaccine development[J]. R Soc Open Sci, 2021, 8(3): 201991. PMCID: PMC8074923. DOI: 10.1098/rsos.201991 . https://www.ncbi.nlm.nih.gov/pubmed/33959354 Cited in this article [1]

[14]	Tuffs SW, Dufresne K, Rishi A, et al. Novel insights into the immune response to bacterial T cell superantigens[J]. Nat Rev Immunol, 2024, 24(6): 417-434. DOI: 10.1038/s41577-023-00979-2 . https://www.ncbi.nlm.nih.gov/pubmed/38225276 Cited in this article [2]

[15]	Bergsten H, Nizet V. The intricate pathogenicity of group A Streptococcus: a comprehensive update[J]. Virulence, 2024, 15(1): 2412745. PMCID: PMC11542602. DOI: 10.1080/21505594.2024.2412745 . https://www.ncbi.nlm.nih.gov/pubmed/39370779 Cited in this article [2]

[16]	Atchade E, De Tymowski C, Grall N, et al. Toxic shock syndrome: a literature review[J]. Antibiotics (Basel), 2024, 13(1): 96. PMCID: PMC10812596. DOI: 10.3390/antibiotics13010096 . https://www.ncbi.nlm.nih.gov/pubmed/38247655 Cited in this article [1]

[17]	Brouwer S, Rivera-Hernandez T, Curren BF, et al. Pathogenesis, epidemiology and control of group A Streptococcus infection[J]. Nat Rev Microbiol, 2023, 21(7): 431-447. PMCID: PMC9998027. DOI: 10.1038/s41579-023-00865-7 . https://www.ncbi.nlm.nih.gov/pubmed/36894668 Cited in this article [1]

[18]

Proft T, Fraser JD. Streptococcus Pyogenes Superantigens: Biological Properties and Potential Role in Disease[M]//Ferretti JJ, Stevens DL, Fischetti VA. Streptococcus Pyogenes: Basic Biology to Clinical Manifestations. 2nd ed. Oklahoma City (OK): University of Oklahoma Health Sciences Center, 2024. Cited in this article [1]

[19]

Lin L, Xu L, Lv W, et al. An NLRP3 inflammasome-triggered cytokine storm contributes to streptococcal toxic shock-like syndrome (STSLS)[J]. PLoS Pathog, 2019, 15(6): e1007795. PMCID: PMC6553798. DOI: 10.1371/journal.ppat.1007795 . https://www.ncbi.nlm.nih.gov/pubmed/31170267 Cited in this article [1]

[20]	Song L, Li X, Xiao Y, et al. Contribution of Nlrp3 inflammasome activation mediated by suilysin to streptococcal toxic shock-like syndrome[J]. Front Microbiol, 2020, 11: 1788. PMCID: PMC7456889. DOI: 10.3389/fmicb.2020.01788 . https://www.ncbi.nlm.nih.gov/pubmed/32922370 Cited in this article [1]

[21]	Frost HR, Guglielmini J, Duchêne S, et al. Promiscuous evolution of group A streptococcal M and M-like proteins[J]. Microbiology (Reading), 2023, 169(1): 001280. PMCID: PMC9993116. DOI: 10.1099/mic.0.001280 . https://www.ncbi.nlm.nih.gov/pubmed/36748538 Cited in this article [1]

[22]

Toledo AG, Bratanis E, Velásquez E, et al. Pathogen-driven degradation of endogenous and therapeutic antibodies during streptococcal infections[J]. Nat Commun, 2023, 14(1): 6693. PMCID: PMC10593946. DOI: 10.1038/s41467-023-42572-0 . https://www.ncbi.nlm.nih.gov/pubmed/37872209 Cited in this article [1]

[23]	Su MSW, Cheng YL, Lin YS, et al. Interplay between group A Streptococcus and host innate immune responses[J]. Microbiol Mol Biol Rev, 2024, 88(1): e0005222. PMCID: PMC10966951. DOI: 10.1128/mmbr.00052-22 . https://www.ncbi.nlm.nih.gov/pubmed/38451081 Cited in this article [1]

[24]

Wierzbicki IH, Campeau A, Dehaini D, et al. Group A streptococcal S protein utilizes red blood cells as immune camouflage and is a critical determinant for immune evasion[J]. Cell Rep, 2019, 29(10): 2979-2989.e15. PMCID: PMC6951797. DOI: 10.1016/j.celrep.2019.11.001 . https://www.ncbi.nlm.nih.gov/pubmed/31801066 Cited in this article [1]

[25]	Cook A, Janse S, Watson JR, et al. Manifestations of toxic shock syndrome in children, Columbus, Ohio, USA, 2010-2017[J]. Emerg Infect Dis, 2020, 26(6): 1077-1083. PMCID: PMC7258457. DOI: 10.3201/eid2606.190783 . https://www.ncbi.nlm.nih.gov/pubmed/32442091 Cited in this article [1]

[26]	Zhang H, Dong J, Huang J, et al. Evaluating antibiotic regimens for streptococcal toxic shock syndrome in children[J]. PLoS One, 2023, 18(10): e0292311. PMCID: PMC10569614. DOI: 10.1371/journal.pone.0292311 . https://www.ncbi.nlm.nih.gov/pubmed/37824534 Cited in this article [3]

[27]	Torimitsu S, Abe H, Makino Y, et al. Streptococcal toxic shock syndrome with fatal outcome: report on four forensic autopsy cases[J]. Leg Med (Tokyo), 2021, 50: 101851. DOI: 10.1016/j.legalmed.2021.101851 . https://www.ncbi.nlm.nih.gov/pubmed/33578046 Cited in this article [2]

[28]	马耀玲, 何颜霞. 链球菌中毒性休克综合征[J] . 中华实用儿科临床杂志, 2022, 37(21) : 1633-1636. DOI: 10.3760/cma.j.cn101070-20220806-00945 Cited in this article [1]

[29]

Hanada S, Wajima T, Takata M, et al. Additional biomarkers and emm types associated with group A streptococcal toxic shock syndrome: a Japanese nationwide observational study[J]. Eur J Clin Microbiol Infect Dis, 2025, 44(6): 1471-1480. PMCID: PMC12116948. DOI: 10.1007/s10096-025-05116-6 . https://www.ncbi.nlm.nih.gov/pubmed/40193020 Cited in this article [1]

[30]	华春珍, 俞蕙, 杨林海, 等. 儿童化脓性链球菌致中毒性休克综合征15例[J]. 中华儿科杂志, 2018, 56(8): 587-591. DOI: 10.3760/cma.j.issn.0578-1310.2018.08.006 . https://www.ncbi.nlm.nih.gov/pubmed/30078239 Cited in this article [1]

[31]

Hasegawa T, Hashikawa SN, Nakamura T, et al. Factors determining prognosis in streptococcal toxic shock-like syndrome: results of a nationwide investigation in Japan[J]. Microbes Infect, 2004, 6(12): 1073-1077. DOI: 10.1016/j.micinf.2004.06.001 . https://www.ncbi.nlm.nih.gov/pubmed/15380776 Cited in this article [1]

[32]	The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition[J]. JAMA, 1993, 269(3): 390-391. https://www.ncbi.nlm.nih.gov/pubmed/8418347 Cited in this article [1]

[33]	Center for Disease Control and Prevention. Toxic shock syndrome (other than streptococcal) (TSS): 2011 case definition[EB/OL]. (2018-03-12)[2022-07-06]. https://ndc.services.cdc.gov/case-definitions/toxic-shock-syndrome-2011/ Cited in this article [1]

[34]

Nanduri SA, Onukwube J, Apostol M, et al. Challenges in surveillance for streptococcal toxic shock syndrome: active bacterial core surveillance, United States, 2014-2017[J]. Public Health Rep, 2022, 137(4): 687-694. PMCID: PMC9257504. DOI: 10.1177/00333549211013460 . https://www.ncbi.nlm.nih.gov/pubmed/33960856 Cited in this article [1]

[35]	Song M, Huang X, Hou Y, et al. Perinatal group A streptococcal infection in vagina and its impact on pregnancy outcomes[J]. Am J Transl Res, 2024, 16(5): 1806-1814. PMCID: PMC11170569. DOI: 10.62347/ZKIE2772 . https://www.ncbi.nlm.nih.gov/pubmed/38883355 Cited in this article [1]

[36]

Barsenga S, Mitiku H, Tesfa T, et al. Throat carriage rate, associated factors, and antimicrobial susceptibility pattern of group A Streptococcus among healthy school children in Jigjiga City, Eastern Ethiopia[J]. BMC Pediatr, 2022, 22(1): 227. PMCID: PMC9040231. DOI: 10.1186/s12887-022-03294-2 . https://www.ncbi.nlm.nih.gov/pubmed/35473515 Cited in this article [1]

[37]	Kim TH. Toxic shock syndrome (TSS) caused by group A Streptococcus: novel insights within the context of a familiar clinical syndrome[J]. J Korean Med Sci, 2024, 39(17): e154. PMCID: PMC11074494. DOI: 10.3346/jkms.2024.39.e154 . https://www.ncbi.nlm.nih.gov/pubmed/38711318 Cited in this article [1]

[38]	Andreoni F, Zürcher C, Tarnutzer A, et al. Clindamycin affects group A Streptococcus virulence factors and improves clinical outcome[J]. J Infect Dis, 2017, 215(2): 269-277. DOI: 10.1093/infdis/jiw229 . https://www.ncbi.nlm.nih.gov/pubmed/27247345 Cited in this article [1]

[39]

Gergova R, Boyanov V, Muhtarova A, et al. A review of the impact of streptococcal infections and antimicrobial resistance on human health[J]. Antibiotics (Basel), 2024, 13(4): 360. PMCID: PMC11047474. DOI: 10.3390/antibiotics13040360 . https://www.ncbi.nlm.nih.gov/pubmed/38667036 Cited in this article [1]

[40]	Gregory CJ, Okaro JO, Reingold A, et al. Invasive group A streptococcal infections in 10 US states[J]. JAMA, 2025, 333(17): 1498-1507. PMCID: PMC11976646. DOI: 10.1001/jama.2025.0910 . https://www.ncbi.nlm.nih.gov/pubmed/40193120 Cited in this article [1]

[41]

Iannelli F, Santoro F, Santagati M, et al. Type M resistance to macrolides is due to a two-gene efflux transport system of the ATP-binding cassette (ABC) superfamily[J]. Front Microbiol, 2018, 9: 1670. PMCID: PMC6079230. DOI: 10.3389/fmicb.2018.01670 . https://www.ncbi.nlm.nih.gov/pubmed/30108557 Cited in this article [1]

[42]	Yang Y, Xie S, He F, et al. Recent development and fighting strategies for lincosamide antibiotic resistance[J]. Clin Microbiol Rev, 2024, 37(2): e0016123. PMCID: PMC11237733. DOI: 10.1128/cmr.00161-23 . https://www.ncbi.nlm.nih.gov/pubmed/38634634 Cited in this article [1]

[43]

Cortés-Penfield N, Ryder JH. Should linezolid replace clindamycin as the adjunctive antimicrobial of choice in group A streptococcal necrotizing soft tissue infection and toxic shock syndrome? A focused debate[J]. Clin Infect Dis, 2023, 76(2): 346-350. DOI: 10.1093/cid/ciac720 . https://www.ncbi.nlm.nih.gov/pubmed/36056891 Cited in this article [1]

[44]

Babiker A, Warner S, Li X, et al. Adjunctive linezolid versus clindamycin for toxin inhibition in β-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation[J]. Lancet Infect Dis, 2025, 25(3): 265-275. PMCID: PMC11871996. DOI: 10.1016/S1473-3099(24)00507-3 . https://www.ncbi.nlm.nih.gov/pubmed/39396526 Cited in this article [1]

[45]

Bryant AE, Bayer CR, Aldape MJ, et al. Emerging erythromycin and clindamycin resistance in group A Streptococci: efficacy of linezolid and tedizolid in experimental necrotizing infection[J]. J Glob Antimicrob Resist, 2020, 22: 601-607. DOI: 10.1016/j.jgar.2020.04.032 . https://www.ncbi.nlm.nih.gov/pubmed/32408046 Cited in this article [1]

[46]

Sriskandan S, Ferguson M, Elliot V, et al. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation[J]. J Antimicrob Chemother, 2006, 58(1): 117-124. DOI: 10.1093/jac/dkl173 . https://www.ncbi.nlm.nih.gov/pubmed/16670109 Cited in this article [1]

[47]

Amreen S, Brar SK, Perveen S, et al. Clinical efficacy of intravenous immunoglobulins in management of toxic shock syndrome: an updated literature review[J]. Cureus, 2021, 13(1): e12836. PMCID: PMC7896483. DOI: 10.7759/cureus.12836 . https://www.ncbi.nlm.nih.gov/pubmed/33628694 Cited in this article [1]

[48]

Schrage B, Duan G, Yang LP, et al. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome[J]. Clin Infect Dis, 2006, 43(6): 743-746. DOI: 10.1086/507037 . https://www.ncbi.nlm.nih.gov/pubmed/16912949 Cited in this article [1]

[49]

Laho D, Blumental S, Botteaux A, et al. Invasive group A streptococcal infections: benefit of clindamycin, intravenous immunoglobulins and secondary prophylaxis[J]. Front Pediatr, 2021, 9: 697938. PMCID: PMC8417895. DOI: 10.3389/fped.2021.697938 . https://www.ncbi.nlm.nih.gov/pubmed/34490159 Cited in this article [1]

[50]

Darenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial[J]. Clin Infect Dis, 2003, 37(3): 333-340. DOI: 10.1086/376630 . https://www.ncbi.nlm.nih.gov/pubmed/12884156 Cited in this article [1]

[51]

Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. The Canadian Streptococcal Study Group[J]. Clin Infect Dis, 1999, 28(4): 800-807. DOI: 10.1086/515199 . https://www.ncbi.nlm.nih.gov/pubmed/10825042 Cited in this article [1]

[52]

Bergsten H, Madsen MB, Bergey F, et al. Correlation between immunoglobulin dose administered and plasma neutralization of streptococcal superantigens in patients with necrotizing Soft tissue infections[J]. Clin Infect Dis, 2020, 71(7): 1772-1775. DOI: 10.1093/cid/ciaa022 . https://www.ncbi.nlm.nih.gov/pubmed/31916575 Cited in this article [1]

[53]	Cho KH. Molecular targets in Streptococcus pyogenes for the development of anti-virulence agents[J]. Genes (Basel), 2024, 15(9): 1166. PMCID: PMC11430994. DOI: 10.3390/genes15091166 . https://www.ncbi.nlm.nih.gov/pubmed/39336757 Cited in this article [3]

[54]

Herrera AL, Van Hove C, Hanson M, et al. Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection[J]. PLoS One, 2020, 15(6): e0235139. PMCID: PMC7310742. DOI: 10.1371/journal.pone.0235139 . https://www.ncbi.nlm.nih.gov/pubmed/32574205 Cited in this article [1]

[55]	Hansen NS, Leth S, Nielsen LT. Toxic shock syndrome[J]. Ugeskr Laeger, 2020, 182(20): V11190673. https://www.ncbi.nlm.nih.gov/pubmed/32400378 Cited in this article [1]

[56]	禹定乐, 卢清华, 尤元海, 等. 中国儿童A族链球菌感染相关疾病的诊断、治疗与预防专家共识 [J]. 中华实用儿科临床杂志, 2022, 37(21): 1604-1618. DOI: 10.3760/cma.j.cn101070-20220815-00974 . Cited in this article [2]